The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia

Francis J. Giles, Gautam Borthakur, Farhad Ravandi, Stefan Faderl, Srdan Verstovsek, Deborah Thomas, William Wierda, Alessandra Ferrajoli, Steven Kornblau, Sherry Pierce, Maher Albitar, Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journalArticle

157 Scopus citations

Abstract

The haematopoietic cell transplantation comorbidity index (HCTCI) predicts nonrelapse mortality and overall survival (OS) post-stem cell transplantation. HCTCI scores were assessed in 177 patients over 60 years of age receiving acute myeloid leukaemia (AML) induction therapy. HCTCI score was 0 in 22% of patients, 1-2 in 30%, and ≥3 in 48%. In patients with scores of 0, 1-2, or ≥3, early death rates were 3%, 11% and 29% (P < 0.001) respectively; median OS was 45, 31 and 19 weeks (P = 0.04) respectively. The HCTCI score is predictive of early death rates and OS in older patients receiving AML induction therapy.

Original languageEnglish (US)
Pages (from-to)624-627
Number of pages4
JournalBritish Journal of Haematology
Volume136
Issue number4
DOIs
StatePublished - Feb 1 2007
Externally publishedYes

Keywords

  • Acute myeloid leukaemia
  • Comorbidity
  • Induction chemotherapy
  • Prognosis

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia'. Together they form a unique fingerprint.

  • Cite this

    Giles, F. J., Borthakur, G., Ravandi, F., Faderl, S., Verstovsek, S., Thomas, D., Wierda, W., Ferrajoli, A., Kornblau, S., Pierce, S., Albitar, M., Cortes, J., & Kantarjian, H. (2007). The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. British Journal of Haematology, 136(4), 624-627. https://doi.org/10.1111/j.1365-2141.2006.06476.x